. 2020 Nov 13;23(3):300–305. doi: 10.4103/aja.aja_61_20

Table 3.

The areas under the receiver operating characteristic curve for prostate-specific antigen density and prostate-specific antigen in predicting the risk of prostate cancer

Variables	PSA 4.0 ng ml⁻¹–10.0 ng ml⁻¹		PSA 10 ng ml⁻¹–20 ng ml⁻¹		PSA above 20 ng ml⁻¹		All PSA

	PCa	HGPCa	PCa	HGPCa	PCa	HGPCa	PCa	HGPCa
Age	0.620	0.630	0.624	0.606	0.575	0.552	0.626	0.617
PSA	0.526	0.524	0.545	0.556	0.650	0.647	0.700	0.726
PV	0.623	0.625	0.666	0.655	0.580	0.568	0.600	0.588
PSAD	0.627	0.630	0.675	0.668	0.675	0.664	0.744	0.760
TRUS	0.513	0.503	0.528	0.517	0.564	0.543	0.535	0.527
%fPSA	0.563	0.563	0.593	0.600	0.560	0.552	0.612	0.617

PSA: prostate-specific antigen; PV: prostate volume; PSAD: prostate-specific antigen density; TRUS: transrectal ultrasound; PCa: prostate cancer; HGPCa: high-grade prostate cancer; %fPSA: the ratio of free-to-total PSA